KR20030030558A - Compositions for the treatment of prostatitis - Google Patents

Abstract

PURPOSE: A therapeutic composition for treatment of prostatic disease containing bamboo salt, Scutellariae Radix, Phellodendri Cortex, Aloe vera extract and Ginkgo biloba leaves is provided. The composition exhibits an excellent therapeutic effect on various prostatic diseases such as prostatitis, prostatomegaly, etc. by direct injection into the bladder and urethra and it is thus effectively used in the treatment of prostatic disease. CONSTITUTION: A blend of 0.1 to 1 part by weight of Scutellariae Radix, 0.1 to 1 part by weight of Phellodendri Cortex, 0.1 to 1 part by weight of an Aloe vera extract and 0.1 to 1 part by weight of Ginkgo biloba leaves is extracted in a solvent and freeze-dried. Thereafter, the freeze-dried product is dissolved in an aqueous solution of 1 to 15 parts by weight of bamboo salt and filtered.

Description

Compositions for the treatment of prostate diseases {Compositions for the treatment of prostatitis}

The present invention relates to a composition for treating prostate disease, and more particularly, to a composition for treating prostate disease consisting of extracts of bamboo salt and golden, yellow and white, presbyopia and encyclopedia.

The prostate gland is an organ that only men have, located under the bladder and inverted at night. The prostate gland is so small that it is hard to find right after birth, but during puberty it grows slightly due to the action of male hormones. Prostate refers to organs of glandular tissue located in front of the lower abdomen of the human body, as can be seen in the proto + state (立) + gland (腺). In other words, the prostate is an organ consisting of glandular tissue that secretes a substance and fibromuscular that surrounds it, which is located behind the pubic bone, under the bladder, and in front of the rectum, and is firmly fixed to them to surround the urethra. to be.

The prostate gland is fixed to the bladder neck above, the urogenital diaphragm below, and to the prostate ligament of the pubic bone in the future. The prostate gland is part of the semen and nourish the sperm to help sperm motility and to protect against urinary tract infections are essential organs for pregnancy, but as the woman's womb ages and causes many diseases Have In other words, a woman's uterus is necessary to become pregnant, but as aging progresses, it may be similar to the occurrence of diseases such as cervical cancer and fibroids.

The prostate secretion opens to the prostate urethral area along 15 to 30 tubes. The prostate gland begins to grow after puberty due to the effects of male hormones and becomes about 20 mg around 30 years of age. When the age of 60 years old or older, the prostate gland becomes larger in size. Prostate hypertrophy does not necessarily require treatment, and how discomfort and pain a patient suffers from is a primary application of treatment. In other words, the improvement of the symptoms complained by the patient is the primary treatment goal. Among these symptoms of enlarged prostate, symptoms such as residual urine (feeling like urine remains after urine), nocturia, daytime urination, thin urine, and lack of urine are high. In addition, symptoms of decreased libido or erectile dysfunction due to enlarged prostate gland are also improved, and the symptom of bloating (wet testis) is also eliminated.

Prostatic hyperplasia is treated with medicinal acupuncture that induces moxibustion in perineal and genital periphery and injects herbal extracts such as sulfur, antler, and ginseng. The effect is due to the direct action of the drug on the enlarged prostate area. It is estimated that symptom may be improved by reducing or repairing bladder dysfunction caused by enlarged prostate. Clinically, studies are underway to reveal the mechanism because the effect of symptom improvement is satisfactory.

In women, the urinary incontinence is difficult to urinate because of the urinary incontinence, but in many cases the urine is difficult to discharge due to the enlarged prostate gland, such prostatic hyperplasia is more than 60 men It is one of the most common diseases that over 50% of people experience. Men with congenital testicles that do not function or have had their testicles removed do not develop an enlarged prostate. In other words, the prostate gland is the target organ of male hormone along with the seminal vesicles. However, molecular biology studies on how male hormones work specifically are actively underway, but many do not know yet, many of them do not yet know the role associated with sexual function.

Prostatitis, on the other hand, accounts for about 25% of male urogenital diseases and is the most common urological disease in men under 50 years of age. Chronic complaints are often relatively intractable, and the cause, diagnosis, and treatment are not well known compared to other prostate diseases such as prostate hyperplasia or prostate cancer.

Literally interpreting prostatitis is a disease that causes inflammation of the prostate gland. However, doctors use slightly different meanings, and pathologists diagnose it as prostatitis if the white blood cells or lymphocytes are present in the prostate tissue. Urologists who diagnose and treat patients with prostatitis sometimes diagnose prostatitis only in abnormal cases where more than 10 leukocytes are found in the prostate fluid when viewed under a high magnification microscope of 400 times. Prostate symptoms, such as the perineal pain commonly found in chronic prostatitis, can be diagnosed as prostatitis, even if they do not increase. The prostatitis can be classified into four groups. First, the first group is acute bacterial prostatitis with acute symptoms and is caused by bacterial infection. Symptoms include sudden high fever and chills, sweating, joint pain and muscle pain, and frequent urination or sleep while urinating. In addition, the urinary tract feels hot when urinating.

The second group is chronic bacterial prostatitis, a recurrent refractory disease that accounts for 5 to 40% of all prostatitis patients. There are various symptoms such as poor urine or urgent urine, frequent urination, awakening and urinating, and lower back pain, perineum (between the testicles and anus) and external genitalia (penis). There may be times when you feel blood and bleeding from the semen.

The third group is chronic pelvic pain syndrome, which can be divided into inflammatory and non-inflammatory. Symptoms vary widely and have symptoms similar to those of chronic bacterial prostatitis, including pain in the lower abdomen, perineum, penis and testes, difficulty urinating, thinning urine, unbearable urine, and frequent urination. They sometimes go to sexual dysfunction.

Group 4 is asymptomatic inflammatory prostatitis and has no subjective symptoms and is found by chance by examination of prostate fluid or biopsy.

There are many ways to treat such prostatitis depending on the symptoms. In the case of acute bacterial prostatitis, broad-spectrum antibiotics are first administered, and in the case of chronic bacterial prostatitis, antibiotics are required. The prostate has a special structure, and only a few antibiotics are effective. Chronic nonbacterial prostatitis or chronic pelvic pain syndrome is poorly treated. Most treatments require more than eight weeks of treatment, including treatment with antibiotics, periodic prostate massage, alpha blockers, analgesics, muscle relaxants, physiotherapy, electrostimulation, and surgical methods. Therapy, exercise, sex, stress reduction, and hot water baths. Antibiotics in theory should not be used when they are non-bacterial, but the administration of antibiotics often relieves symptoms, so they are generally used for the treatment of prostatitis. Alpha-blockers act to ease urinary excretion by inhibiting the contraction of the bladder neck and prostate smooth muscles to relax functional occlusions. Side effects mainly affect the cardiovascular and nervous system, causing fatigue, headache, or orthostatic hypotension. . Painkillers, muscle relaxants, physiotherapy, and electrical stimulation treatments are symptomatic treatments for pain relief and are not fundamental treatments.

Thus, the present inventors prepared a composition in which golden, yellowish white, rosacea and encyclopaedia ethanol extracts were added to an aqueous solution of bamboo salt in order to treat such prostate diseases, and the drug was injected directly into the bladder and urethra by injecting the composition into the inflammation site. The present invention was completed by revealing that it can be directly absorbed to treat various prostate diseases such as prostatitis and enlarged prostate.

It is an object of the present invention to provide a composition for treating prostate disease.

1 is a graph showing the relative effects of the composition for the treatment of prostate disease of the present invention on erection, sexual desire and ejaculation.

A; Erection, B; Libido, C; Ejaculation

□; Before treatment; After treatment

In order to achieve the above object, the present invention provides a composition for treating prostate disease, including bamboo salt, gold, yellowish white, presbyopia and encyclopedia.

The present invention also provides a method for preparing the composition for treating prostate disease.

Hereinafter, the present invention will be described in detail.

The present invention provides a composition for treating prostate disease in which bamboo salt, gold, yellowish white, rot and encyclopedia were dissolved.

In the composition of the present invention, the constituent ratios of bamboo salt, gold, yellowish white, rosacea and encyclopaedia are 1 to 15 parts by weight: 0.1 to 1 part by weight: 0.1 to 1 part by weight: 0.1 to 1 part by weight: 0.1 to 1 part by weight, respectively. Preferably, it is more preferable that it is 12 weight part: 0.5 weight part: 0.5 weight part: 0.5 weight part: 0.5 weight part.

The composition of the present invention takes the weight part of bamboo salt, golden, yellowish white, presbyopia and encyclopaedia, among which golden, yellowish white, presbyopia and encyclopaedia extract is extracted using an extracting solvent, after blowing the extracting solvent to obtain a residue, water Prepared by dissolving bamboo salt and the above residues of golden, yellowish white, presbyopia and encyclopedia. The final composition of the present invention thus obtained is 1-15 w / v% bamboo salt 0.01-0.1 w / v% gold: 0.01-0.1 w / v% yellow-white: 0.01-0.1 w / v% presbyopia 0.01-0.1 It is preferable that it is an aqueous solution of w / v%, The aqueous solution which is 12 w / v% of bamboo salt, 0.05 w / v% of golden yellow, 0.05 w / v% of yellow-white, 0.05 w / v% of presbyopia, and 0.05 w / v% of encyclopedia is more desirable.

Golden, yellowish white, and presbytery release the heat that is bound together and make it lively.They are born again (to remove the salty times and to make new flesh), and the salt acts as a ham (salty) to the lower part of the human body to make it soft. Softens and releases clumps), releases toxins and anti-inflammatory. Therefore, by using the medicinal herbs to treat the inflammation of the prostatitis and thereby a variety of symptoms that can be fundamentally improved, and gently relieve the enlarged lesions of the enlarged prostate, improve the symptoms.

It is well known that there is antibacterial and antiviral activity in gold used in the composition of the present invention. Golden extract has an inhibitory effect on staphylococcus aureus, gonococci, etc. In particular, gonococcal suppression action is good for the treatment of sexually transmitted diseases, especially in the form of vulva cleaning solution to prevent and treat causative bacteria infection. It also promotes anti-inflammatory and fine-immunity and also relaxes the spasms of smooth muscle. Yellow and white baekbaek acts on the ulcers (wounds or inflammation) and has an effective antimicrobial action against a relatively wide range of pathogenic microorganisms. In addition, anti-ulcer action has been shown to inhibit the cell damage.

Presbytery has a traumatic action that shortens wound healing and promotes cell renewal. It also has antibacterial and anti-inflammatory effects and promotes macrophage proliferation.

Encyclopaedia has excellent antibacterial activity, promotes blood circulation, and relaxes vascular smooth muscle. (全國 社科 大學 本草 學 敎 授: 本草 學, Seoul, 永 林 社, 1991; 安德 均: 韓國 本草 圖鑑, Seoul, University of Korea, 1998; Andeok, Kimbeol: University, Seoul, Ijungsa, 1997; Yeongin, Andeung, Seoul, Seoul, Seongsa, 1982; Deok-gyun Ahn, Chang-min Kim, Min-kyo Lee, Kyung-soon Lee: Seoul National University, Seoul, 1998;天津 科學 技術 出版社, 1997).

The composition of the present invention is to treat the prostate gland by directly injecting the drug without taking the drug, thereby quantitatively and qualitatively alleviating the symptom for perineal pain, day and night urinary frequency and residual urine, which are most appealed by prostate patients.

Prostate disease is a disease that is difficult to treat in both cases, and the method of enhancing the therapeutic effect by using the composition of the present invention as a herbal medicine in the catheter injection method that is commonly used in the present invention, IPSS (International Prostate Symptom Score) and NIH-CPSI As such, the internationally recognized verification method increased the reliability of the research. The scores on the questionnaire using IPSS and NIH-CPSI are not perfect, but they provide excellent guidance for objectively analyzing prostate disease (see Tables 2 and 3 ) (Kwon SM, Kim SI, Chun DC, Cho NH, Chung BC, Park BW, Hong SJ., Yonsei Med. J. , 2001 , 42 (4), 395-404; Moon TD, Hagen L, Heisey DM., Urology , 1997 , 50 (5), 700-703; Serel TA, Kosar A, Ozturk A, Dogruer K, Tahoglu M, Kecelioglu M., Int.Urol.Neprol. , 1997 , 29 (1), 53-58; Ku JH, Kim ME, Lee NK, Park YH., Urol.Res . , 2001 , 29 (2), 108-112; Nickel JC, Johnston B, Downey J, Barkin J, Pommerville P, Gregoire M, Ramsey E., Urology , 2000 , 56 (3), 413-417 ).

In order to treat prostate disease with the composition of the present invention, the herbal extract is first injected into the bladder and urethra through the urethra, and then the patient is allowed to hold the end of the urethra so that the herbal extract injected into the urethra does not flow. It takes about 10 to 15 minutes for a single procedure, and there is no risk of infection because the herbal extract used in the procedure and all surgical instruments are used for a single sterilization system. On average, the procedure is effective more than five times, and symptoms are almost lost after about ten procedures. The composition of the present invention injected into the urethra and bladder causes osmotic pressure directly on the bladder tissue, the prostate, and the urethra tissue to remove impurities and inflammation in the tissue, and also promotes natural regeneration of the tissue and causes anti-inflammatory and anti-inflammatory action.

The present inventors compared IPSS and NIH-CPSI in patients with chronic prostate disease, and in IPSS, they were in their 40s, 50s, 30s, and 60s. In the case of moderate patients with symptomatic scores ranging from 8 to 24 points after treatment, the number of treatments that started to be effective began from 8 times, and the treatment efficiency was 42.9 for 9 and 10 treatments, respectively. % And 77.4%.

In the NIH-CPSI, ages were in their 40s, 50s, 30s, and 60s, and in the 30s and 50s, the average patient improved with a symptom score of 8 to 24. In order of age, 40s and 60s.

From the above results, it can be seen that treatment efficiency with respect to age in both IPSS and NIH-CPSI tends to be similar. The number of treatments was also effective in 8 (25.0%), 9 (60.0%) and 10 (82.6%). As such, both IPSS and NIH-CPSI showed a similar tendency to 77.4% and 82.6% for 10 treatments. Thus, the composition of the present invention shows the best treatment effect when treated 10 or more times in chronic prostate patients. It can be seen that the treatment efficiency is good. After treating chronic prostate disease with the composition of the present invention, perineal pain was improved to 72.8%, day and night urinary frequency was 74.5%, residual urination was improved to 74.5%, and erectile power was increased by 88.0%, sexual desire was increased by 86.0%, and ejaculation was 80.0% showed improvement (see Tables 4 to 7 and FIG. 1 ).

In conclusion, the composition of the present invention showed an excellent effect on chronic prostate disease, it was confirmed that the catheter injection method using the composition of the present invention can be very useful for the treatment of prostate disease.

The present invention also provides a method for preparing the composition for treating prostate disease.

Method for producing a composition for treating prostate disease of the present invention

1) 1 to 15 parts by weight of bamboo salt, 0.1 to 1 part by weight of gold, 0.1 to 1 part by weight of yellow and white, 0.1 to 1 part by weight of presbyopia, and 0.1 to 1 part by weight of encyclopedia

2) extracting the golden, yellowish white, rosacea and encyclopedia with an extraction solvent to prepare an extract;

3) preparing a lyophilisate for each extract of step 2;

4) preparing an aqueous solution of bamboo salt;

5) dissolving each lyophilisate of step 3 in the bamboo salt solution of step 4; And

6) filtering the composition of step 5.

In step 4, the aqueous solution of bamboo salt is preferably at a concentration of 1 to 15 w / v%, more preferably at a concentration of 12%.

In addition, in step 5, each lyophilisate is preferably dissolved at a concentration of 0.01 to 0.1 w / v%, more preferably 0.05 w / v%. In this case, since 10 g of the lyophilisate is prepared for each 100 g of the drug, 0.1 to 1 part of the extract may be said to be dissolved.

Hereinafter, the present invention will be described in detail by way of examples.

However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.

Example 1 Preparation of a Composition for Treating Prostate Disease

In order to prepare a composition for treating prostate disease of the present invention, firstly, the present inventors prepared golden, yellowish white, rosacea and encyclopaedia ethanol extracts. Specifically, 500 g of gold was crushed using a manual crusher and placed in a flask containing 1 L of 70% ethanol, extracted with an ultrasonic shaker (Daeil Lab Service, Seoul) for 10 minutes at room temperature, and the supernatant was collected. Again the pellets (pellets) were sequentially extracted using 80%, 90% and 100% ethanol in the same manner as above and then the supernatants were mixed with each other. The filtrate was concentrated with a vacuum condenser (EYELA Co. Japan) and then dried with a freeze dryer (EYELA Co. Japan) to obtain 50 g of a golden freeze dried product. Freeze-dried products were obtained in the same manner as in the case of the golden yellow, presbyopia and encyclopedia.

Next, the present inventors dissolved 12 g of bamboo salt in 100 ml of tertiary distilled water to prepare a 12% solution, and dissolved 0.05 g of the lyophilized product of the ethanol extracts of golden, yellowish white, rosacea and encyclopedia prepared above. After repeated filtering three times with a 0.25 ㎛ filter to prepare a composition for treating prostate disease of the present invention.

Experimental Example 1 Measurement of the Effect of the Composition of the Present Invention on Prostate Disease

<1-1> Research subject

The present inventors were diagnosed with chronic prostate disease through subjective symptoms and objective questionnaire from January 1, 2001 to August 31, 2001. The effects of the composition of the present invention on prostate disease were analyzed in 98 patients treated with oriental medicine.

The age distribution of 98 patients with chronic prostate disease was 28.6% in their 40s and 26.5% in their 50s, accounting for 55.1% of the total, and 18.4% in their 30s and 17.4% in their 60s, respectively. The ratio was relatively low at 5.1% and 4.1% ( Table 1 ).

Age distribution age Actual number of people (ratio) 70 ↑ 4 (4.1) 60-69 17 (17.4) 50-59 26 (26.5) 40-49 28 (28.6) 30-39 18 (18.4) 29 ↓ 5 (5.1) all(%) 98 (100.0)

<1-2> Research method

In order to investigate the effect of the composition on prostate disease, the present inventors pushed a catheter (French 8, Camel, Korea) having a diameter of 3 mm and a length of 37 cm into the bladder and then prepared in Example 1 After injecting 60 ml of the therapeutic composition into the bladder and injecting 20 ml into the urethra again, the patient was allowed to hold the end of the urethra for 10 minutes to prevent the drug injected into the urethra from flowing out. The catheterization procedure was performed on all 98 patients who were studied for 10 times, once every 3 days.

<1-2-1> Criteria

Based on subjective symptoms and history of all 98 patients, the inventors set criteria for prostate disease through objective questionnaires of the International Prostate Symptom Score (IPSS) and Chronic Prostate Symptom Score (NIH-CPSI). It was. The diagnostic criteria of the International Prostate Symptom Score (IPSS) and Chronic Prostate Symptom Score (NIH-CPSI) are shown in Tables 2 and 3 below.

IPSS Index for Chronic Prostatitis Total count IPSS Index 0 normal 1-7 Rare 8-24 Medium 25 ↑ Severe

NIH-CPSI Index for Chronic Prostatitis Total count NIH-CPSI Index 0 normal 1-9 Rare 10-18 Medium 19-31 Severe

<1-3> IPSS analysis according to the number of treatment of the composition for the treatment of prostate disease

Among the patients who were treated from 1 to 10 times, 33 patients were treated from 1 to 7 times, accounting for 33.7% of the total, and the treatment efficiency was very low in these patients. Nine patients (9.2%), 9 patients (9.2%), 10 patients (47) (48.0%) received 10 treatments. In moderate patients with symptom scores ranging from 8 to 24, the number of treatments that started to be effective in the case of symptom improvement after treatment was from eight times, and the treatment efficiency was 14.3%. One case was 42.9% and the other 10 times was 77.4% ( Table 4 ).

Relative frequency and effectiveness of treatment by IPSS Number of treatments Normal (0) Insignificant (1-7) Moderate (8-24) Severe (25 ↑) Actual number of people (ratio) One · 0/1 0/3 · 0/4 2 · · 0/8 · 0/8 3 · · 0/3 · 0/3 4 · · 0/7 · 0/7 5 · 0/1 0/3 · 0/4 6 · · 0/5 · 0/5 7 · 0/1 0/1 · 0/2 8 · 0/1 1/7 (14.3) 0/1 1/9 (11.1) 9 · 0/1 3/7 (42.9) 1/1 (100.0) 4/9 (44.4) 10 0/4 5/10 (50.0) 24/31 (77.4) 2/2 (100.0) 31/47 (66.0) Total 0/4 5/15 (33.3) 28/75 (37.3) 3/4 (75.0) 36/98 (36.7)

<1-4> IPSS Analysis of Treatment Efficiency According to Age of Prostate Disease Therapeutic Composition

Among 98 patients with chronic prostate disease, the age distribution accounted for 28.6% in their 40s and 26.5% in their 50s, followed by 18.4% in their 30s, 17.4% in their 60s, and 5.1% and 4.1% in those under 29 and over 70, respectively. In the case of moderate patients, the treatment efficiency by age group showed the highest as 54.6% in the 40s and 50% in the 30s, followed by 21.1% in the 50s and 14.3% in the 60s ( Table 5 ).

Relative age and treatment effect by IPSS analysis age normal(%) Insignificant (%) Moderate (%) seriousness(%) Actual number of people (ratio) 70 ↑ · · 1/2 (50.0) 2/2 (100.0) 3/4 (75.0) 60-69 · 0/2 2/14 (14.3) 1/1 (100.0) 3/17 (17.7) 50-59 · 2/6 (33.3) 4/19 (21.1) 1/1 (100.0) 7/26 (26.9) 40-49 0/3 1/2 (50.0) 12/22 (54.6) 1/1 (100.0) 14/28 (50.0) 30-39 · 2/6 (33.3) 6/12 (50.0) · 8/18 (44.4) 29 ↓ 0/1 0/1 1/3 (33.3) · 1/5 (20.0) Total 0/4 5/17 (29.4) 26/72 (36.1) 5/5 (100.0) 36/98 (36.7)

<1-5> NIH-CPSI analysis according to the number of treatment of the composition for the treatment of prostate disease

As a result of analysis of patients who received treatment from 1 to 10 times, 15 patients received less than 3 treatments, 15.3%, 4 times 2 people (2.0%), 5 times 1 person (1.0%), 6 times Three (3.1%), seven (1) (1.0%), eight (3) (3.1%), nine (5) (5.1%), and ten (38) (38.8%). In the case of moderate patients, the number of treatments that started to be effective was from 8 times and the treatment efficiency was 25.0%, followed by 9 times 60.0% and 10 times 82.6% ( Table 6 ).

Relative frequency and effectiveness of treatment by NIH-CPSI analysis Number of treatments normal Insignificant Moderate seriousness Actual number of people (ratio) One · 0/1 0/3 · 0/4 2 · 0/1 0/5 0/2 0/8 3 · · 0/2 0/1 0/3 4 · · 1/3 1/4 (25.0) 2/7 (28.6) 5 · · 1/2 0/2 1/4 (25.0) 6 · · 0/2 3/3 (100.0) 3/5 (60.0) 7 · · 0/1 1/1 (100.0) 1/2 (50.0) 8 · · 1/4 (25.0) 2/5 (40.0) 3/9 (33.3) 9 · · 3/5 (60.0) 2/4 (50.0) 5/9 (55.6) 10 · 0/5 19/23 (82.6) 19/19 (100.0) 38/47 (80.9) all 0 0/7 25/50 (50.0) 28/41 (68.3) 53/98 (54.1)

<1-6> NIH-CPSI Analysis of Treatment Efficiency According to Age of Prostate Disease Therapeutic Composition

Among 98 patients with chronic prostate disease, the age distribution was in their 40s (28.6%), in their 50s (26.5%), in their 30s (18.4%), in their 60s (17.4%), under 29 (5.1%), and over 70 (4.1). %) The treatment efficiency by age was moderate to 29 years old, 30s, 50s, 40s, 70s and 60s, and in the severe group, 70s and above, 30s and 29s. , 50s, 60s, 40s ( Table 7 ).

Relative age and treatment effect by NIH-CPSI analysis age normal Insignificant Moderate seriousness Actual number of people (ratio) 70 ↑ · 0/1 1/2 (50.0) 1/1 (100.0) 2/4 (50.0) 60-69 · 0/2 2/9 (22.2) 4/6 (66.7) 6/17 (35.3) 50-59 · 0/3 8/14 (57.1) 6/9 (66.7) 14/26 (53.9) 40-49 · · 10/19 (52.6) 4/9 (44.4) 14/28 (50.0) 30-39 · 0/1 3/5 (60.0) 10/12 (83.3) 13/18 (72.2) 29 ↓ · · 1/1 (100.0) 3/4 (75.0) 4/5 (80.0) all(%) · 0/7 25/50 (50.0) 28/41 (68.3) 53/98 (54.1)

<1-7> Measurement of effects on perineal pain, day and night urination, and residual urination

Based on the International Prostate Symptom Score (IPSS) and Chronic Prostate Symptom Score (NIH-CPSI), we observed and diagnosed 98 patients individually for perineal pain, day and night urine, and residual urine.

As a result, the perineal pain, day and night urinary frequency, and residual urinalysis felt by the patient after treatment with the composition for treating prostate disease of the present invention were significantly improved after 7 treatments, and the perineal pain was 72.8% after 10 treatments. Frequent urination improved to 74.5% and residual urine to 74.5%.

<1-8> Measurement of effects on erection, sex drive and ejaculation

The present inventors presented objective indicators after converting erection, sex drive and ejaculation power into scores before and after treatment. At this time, the normal state is 0 points, good 1 point, very good 2 points, bad -1 point, very bad-2 point to make a reference score and measure the value of the composition for treating prostate disease of the present invention The effect on the disease was investigated.

As a result, when the composition for treating prostate disease of the present invention was administered by urinary catheterization, the erectile power, sex drive and erectile ability were 88.0%, 86.0% and 80.0%, respectively. According to the age, erectile ability improved in the order of 30s, 50s, 40s, and 60s, and sexual desire was in the order of 30s, 50s, 40s, and 60s. 40s, 60s in order ( Fig. 1 ).

As described above, the composition for treating prostate disease of the present invention is directly injected into the bladder and urethra using the catheter injection method, so that the drug is directly absorbed into the inflammatory site using an osmotic pressure difference, such as prostatitis and prostatic hyperplasia. Since it has an excellent effect on prostate disease, it can be usefully used for the treatment of prostate disease.

Claims (8)

Bamboo salt 1-15 parts by weight: golden 0.1-1 parts by weight: 0.1-1 parts by weight of yellow and white: 0.1-1 parts by weight of presbytery: composition for treating prostate disease comprising 0.1-1 parts by weight of encyclopedia. The method of claim 1, wherein the golden, yellowish white, rosacea and encyclopaedia is an aqueous solution prepared by dissolving the residue obtained by blowing the extraction solvent after extraction with the extraction solvent and dissolving the bamboo salt therein. Composition. The aqueous solution of claim 2 has a concentration of 1 to 15 w / v% of bamboo salt, 0.1 to 0.01 w / v% of gold, 0.1 to 0.01 w / v% of sulfur white, and 0.1 to 0.01 w / v% of presbyopia. 0.01 w / v%, the concentration of the encyclopedia is 0.1 to 0.01 w / v% composition for the treatment of prostate disease. 1) 1 to 15 parts by weight of bamboo salt, 0.1 to 1 part by weight of gold, 0.1 to 1 part by weight of yellow and white, 0.1 to 1 part by weight of presbyopia, and 0.1 to 1 part by weight of encyclopedia 2) extracting the golden, yellowish white, rosacea and encyclopedia with an extraction solvent to prepare an extract; 3) preparing a lyophilisate for each extract of step 2; 4) preparing an aqueous solution of bamboo salt; 5) dissolving each lyophilisate of step 3 in the bamboo salt solution of step 4; And 6) A method for producing a composition for treating prostate disease according to claim 1, comprising the step of filtering the composition of step 5. The method according to claim 4, wherein the aqueous solution of bamboo salt of step 4 is at a concentration of 1 to 15 w / v%. The method according to claim 5, wherein the bamboo salt aqueous solution is 12 w / v% concentration. 5. A process according to claim 4 wherein each lyophilisate of step 5 is dissolved at a concentration of 0.01 to 0.1 w / v%. 8. A process according to claim 7, wherein each lyophilisate is dissolved at a concentration of 0.05 w / v%.